Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.43 |
| ▸ | CD74 | P04233 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL692229 | 0.81 | ELANE (0.66) | ELANEALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL258516 | 0.76 | KMT2A (0.62) | ELANEALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL4216662 | 0.75 | KMT2A (0.59) | ALDH1A1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL692707 | 0.73 | ELANE (0.68) | ELANEMAPTKMT2AKDM4EPOLB | |
| SCHEMBL12352090 | 0.73 | ELANE (1.00) | ELANEALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL6152188 | 0.72 | MAPT (0.56) | ALDH1A1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL4753250 | 0.72 | ALDH1A1 (0.56) | ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL10469445 | 0.72 | MAPT (0.56) | ALDH1A1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL69953 | 0.72 | MAPT (0.62) | ALDH1A1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL12352014 | 0.72 | ELANE (0.66) | ELANEALDH1A1NPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897761-B2 | Heterocyclic compound | FUJIFILM CORPORATION (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7897761-B2 | Heterocyclic compound | FUJIFILM CORPORATION (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20100004439-A1 | Heterocyclic Compound | FUJIFLM CORPORATION (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004439-A1 | Heterocyclic Compound | FUJIFLM CORPORATION (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | FUJIFILM CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | FUJIFILM CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | CYP2A6, CYP2B6, XPO6 | ELANE 1479/4885ALDH1A1 1360/4885MAPT 4345/4885 |
| US-20100004439-A1 | Heterocyclic Compound | PTGER1, CYP1A1, ALOX12 | ELANE 1343/4885ALDH1A1 1205/4885MAPT 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.